This invention relates to a composition comprising a tramadol material and acetaminophen, and its use. As used herein tramadol refers to various forms of tramadol. The compositions are pharmacologically useful in treating pain and tussive conditions. The compositions are also subject to less opioid side-effects such as abuse liability, tolerance, constipation and respiratory depression. Furthermore, where the components of the compositions are within certain ratios the pharmacological effects of the compositions are superadditive (synergistic).
|
0. 31. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:5 to about 1:50.
0. 43. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:5 to about 1:19.
0. 55. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:19 to about 1:50.
0. 16. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:1 to about 1:1600.
0. 67. A pharmaceutical composition consisting essentially of:
an active ingredient that consists of racemic tramadol hydrochloride and acetaminophen, wherein the ratio of racemic tramadol hydrochloride to acetaminophen is from about 1:5 to about 1:19; and
a pharmaceutically acceptable carrier.
0. 1. A pharmaceutical composition comprising a tramadol material and acetaminophen, wherein the ratio of the tramadol material to acetaminophen is a weight ratio from about 1:1 to about 1:1600.
0. 2. The pharmaceutical composition of
0. 3. The pharmaceutical composition of
0. 4. The pharmaceutical composition of
0. 5. The pharmaceutical composition of
6. The pharmaceutical composition of
0. 7. The pharmaceutical composition of
0. 8. The pharmaceutical composition of
0. 9. The pharmaceutical composition of
0. 10. The pharmaceutical composition of
0. 11. The pharmaceutical composition of
0. 12. The pharmaceutical composition of
0. 13. The pharmaceutical composition of
0. 14. The pharmaceutical composition of
15. A method for treating a pain in a mammal comprising an administration administering to the mammal an effective amount of the pharmaceutical composition of
0. 17. The pharmaceutical composition of
0. 18. The pharmaceutical composition of
0. 19. The pharmaceutical composition of
0. 20. The pharmaceutical composition of
0. 21. The pharmaceutical composition of
0. 22. The pharmaceutical composition of
0. 23. The pharmaceutical composition of
0. 24. The pharmaceutical composition of
0. 25. The pharmaceutical composition of
0. 26. The pharmaceutical composition of
0. 27. The pharmaceutical composition of
0. 28. The pharmaceutical composition of
0. 29. The pharmaceutical composition of
0. 30. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of
0. 32. The pharmaceutical composition of
0. 33. The pharmaceutical composition of
0. 34. The pharmaceutical composition of
0. 35. The pharmaceutical composition of
0. 36. The pharmaceutical composition of
0. 37. The pharmaceutical composition of
0. 38. The pharmaceutical composition of
0. 39. The pharmaceutical composition of
0. 40. The pharmaceutical composition of
0. 41. The pharmaceutical composition of
0. 42. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of
0. 44. The pharmaceutical composition of
0. 45. The pharmaceutical composition of
0. 46. The pharmaceutical composition of
0. 47. The pharmaceutical composition of
0. 48. The pharmaceutical composition of
0. 49. The pharmaceutical composition of
0. 50. The pharmaceutical composition of
0. 51. The pharmaceutical composition of
0. 52. The pharmaceutical composition of
0. 53. The pharmaceutical composition of
0. 54. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of
0. 56. The pharmaceutical composition of
0. 57. The pharmaceutical composition of
0. 58. The pharmaceutical composition of
0. 59. The pharmaceutical composition of
0. 60. The pharmaceutical composition of
0. 61. The pharmaceutical composition of
0. 62. The pharmaceutical composition of
0. 63. The pharmaceutical composition of
0. 64. The pharmaceutical composition of
0. 65. The pharmaceutical composition of
0. 66. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of
0. 68. The pharmaceutical composition of
0. 69. The pharmaceutical composition of
0. 70. The pharmaceutical composition of
0. 71. The pharmaceutical composition of
0. 72. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of
0. 73. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of
0. 74. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of
0. 75. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of
0. 76. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of
|
|||||||||||||||||||||||||||||||||||||||||||
This case is related to application Ser. Nos. 7/759,259, filed Sep. 13, 1991, now U.S. Pat. No. 5,223,541 and 07/785,137, filed Oct. 30, 1991, now abandoned, and is a continuation-in-part of application serial No. 07/755,924, filed Sep. 6, 1991, now abandoned. Claims priority, application Germany, filed Apr. 2, 1963, C29547 IV b/12o and application Germany, filed Apr. 2, 1963, C29548 IVd/12p.
U.S. Pat. No. 3,652,589 discloses a class of analgesic cycloalkanol-substituted phenol esters having a basic amine group in the cycloalkyl ring. The compound (1RS, 2RS)-[(dimethylamino)-methyl]-1-(3-methoxy-phenyl)cyclohexanol, commonly known as tramadol, is specifically disclosed therein. A series of articles pertaining to the pharmacology, toxicology and clinical studies of tramadol are found in Arzneim. Forsch, (Drug Res.), 28(I), 114(1978). Driessen et al., Arch. Pharmacol., 341, R104 (1990) disclose that tramadol produces its analgesic effect through a mechanism that is neither fully opioid-like or non-opioid-like. The Abstracts of the VI th World Congress on Pain, Apr. 1-6 (1990), disclose that tramadol hydrochloride is an orally active pure agonist opioid analgesic. However, clinical experience indicates that tramadol lacks many of the typical side effects of opioid agonists, e.g., respiratory depression (W.-Vogel et al., Arzneim. Forsch. (Drug Res.), 28(I), 183 (1978)), constipation (I. Arend et al., Arzneim. Forsch, (Drug Res.), 28(I), 199 (1978)), tolerance (L. Flohe et, al., Arzeim. Forsch, (Drug Res.), 28(I), 213 (1978)), and abuse liability (T. Yanagita, Arzneim. Forsch, (Drug Res.), 28(I), 158 (1978)). When given at a dose of 50 mg by rapid i.v. injection, tramadol may produce certain side effects unique to tramadol including hot flushes and sweating. Despite these side effects, tramadol's combination of non-opioid and opioid activity makes tramadol a very unique drug. Tramadol is currently being marketed by Grunenthal GMBH as an analgesic.
Opioids have for many years been used as analgesics to treat severe pain. They, however, produce undesirable side effects and as a result cannot be given repeatedly or at high doses. The side effect problems are well documented in the literature. See, for example, J. Jaffe and W. Martin in chapter 15, “The Pharmacological Basis of Therapeutics”, editors L. Goodman and A. Gilman, 5th Edition, 245 (1975) wherein it is disclosed that morphine and its congeners, e.g., codeine, hydrocodone and oxycodone, are opioid agonist analgesics that exhibit side effects such as respiratory depression, constipation, tolerance and abuse liability.
As alternatives to using opioids, non-opioids such as acetaminophen (APAP) and aspirin are used as analgesics. APAP, like aspirin, is not subject to the tolerance, addiction and toxicity of the opioid analgesics. However, APAP and aspirin are only useful in relieving pain of moderate intensity, whereas the opioid analgesics are useful in relieving more intense pain; See Woodbury, D. and Fingl, E. in “The Pharmacological Basis of Therapeutics”, 5th Ed.; Goodman, L. and Gilman, A., Chapter 15, pages 325 (1975).
To reduce the side effect problems of opioids, opioids have been combined with other drugs including non-opioid analgesic agents, which lowers the amount of opioid needed to produce an equivalent degree of analgesic. It has been claimed that some of these combination products also have the advantage of producing a synergistic analgesic effect. For example, A. Takemori, Annals New York Acad. Sci., 281, 262 (1976) discloses that compositions including combinations of opioid analgesics with drugs other than analgesics exhibit a variety of effects, i.e., subadditive (inhibitory), additive or superadditive. R. Taber et al., J. Pharm. Expt. Thera., 169(1), 29 (1969) disclose that the combination of morphine and methadone, another opioid analgesic, exhibits an additive effect. U.S. Pat. No. 4,571,400 discloses that the combination of dihydrocodeine, an opioid analgesic, and ibuprofen, a non-opioid analgesic, provides super-additive effects when the components are within certain ratios. A. Pircio et al., Arch. Int. Pharmacodyn., 235, 116 (1978) report superadditive analgesia with a 1:125 mixture of butorphanol, another opioid analgesic, and acetaminophen (APAP), a non-opioid analgesic, whereas a 1:10 mixture did not show any statistically significant superadditive analgesia.
Combinations of non-opioid analgesics have also been prepared to avoid the side effects associated with opioids, and the combinations are noted to have the benefit of requiring less of each ingredient and in producing superadditive effects. G. Stacher et. al., Int. J. Clin. Pharmacol. Biopharmacy, 17, 250 (1979) report that the combination of non-opioid analgesics, i.e., tolmetin and APAP, allows for a marked reduction in the amount of tolmetin required to produce analgesia. In addition, U.S. Pat. No. 4,260,629 discloses that an orally administered composition of APAP and zomepirac, a non-opioid analgesic, in a particular weight ratio range produces a superadditive relief of pain in mammals. Furthermore, U.S. Pat. No. 4,132,788 discloses that 5-aroyl-1-(lower)alkylpyrrole-2-acetic acid derivatives, non-opioid analgesics, when combined with APAP or aspirin exhibit superadditive antiarthritic activity. However, there have been warnings against the daily consumption of non-opioid analgesic mixtures and of the consumption of a single non-opioid analgesic in large amounts or over long periods (see, D. Woodbury and E. Fingl at page 349).
The prior art, however, does not disclose that tramadol an ‘atypical’ opioid analgesic, can or should be combined with another analgesic to lessen the side effects of each or to yield a composition comprising a tramadol material and another analgesic that exhibits superadditive analgesia.
It has now been found that a tramadol material which includes various forms of tramadol as defined hereinafter can be combined with APAP to produce analgesia. The combination employs lesser amounts of both the tramadol material and APAP than would be necessary to produce the same amount of analgesia if either was used alone. By using lesser amounts of both drugs the side effects associated with each are reduced in number and degree. Surprisingly, the compositions comprising the tramadol material and APAP have been found to exhibit synergistic analgesic effects when combined in certain ratios. The compositions according to this invention may also be useful in treating tussive conditions.
The present invention is directed to compositions comprising a tramadol material and acetaminophen. The tramadol material is any one of (1R, 2R or 1S, 2S)-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol (tramadol), its N-oxide derivative (“tramadol N-oxide”), and its O-desmethyl derivative (“O-desmethyl tramadol”) or mixtures thereof. It also includes the individual stereoisomers, mixtures of stereoisomers, including the racemates, pharmaceutically acceptable salts of the amines, such as the hydrochloride salts, solvates and polymorphs of the tramadol material. Tramadol is commercially available from Grunenthal or may be made by the process described in U.S. Pat. No. 3,652,589, which is herein incorporated by reference.
Tramadol N-oxide is prepared by treating tramadol as a free base with an oxidizing agent, e.g., hydrogen peroxide (30%), in an organic solvent, e.g., methanol or isopropanol, with, bit preferably without heating. See, “Reagents For Organic Synthesis”, 1, 471, Fieser & Fieser eds. Wiley N.Y.; (1987), B. Kelentey et al., Arzneim, Forsch., 7, 594 (1957). With heating, the reaction takes about 1 hour, whereas without heating the reaction takes about 3 days. Following the oxidation, the mixture is treated with an agent, e.g. PtO2 or preferably Pt/C, for about a day, to destroy the excess hydrogen peroxide. The mixture is filtered, followed by the evaporation of the filtrate and then the residue is recrystallized from an organic solvent mixture, e.g., methylene chloride/ethyl acetate.
O-Desmethyl tramadol is prepared by treating tramadol as a free base under O-desmethylating reaction conditions, e.g., reacting it with a strong base such as NaH or KH, thiophenol and diethylene glycol (DEG) with heating to reflux. See, Wildes et al., J. Org. Chem., 36, 721 (1971). The reaction takes about an hour, followed by the cooling and then quenching in water of the reaction mixture. The quenched mixture if acidified, extracted with an organic solvent such as ethyl ether, basified and then extracted with a halogenated organic solvent such as methylene chloride. The extract is then dried and the solvent evaporated to yield the O-desmethyl product, which may then be short-path distilled, converted to its corresponding salt, e.g., treated with an acidified (HCl/ethanol) solution, and recrystallized from an organic solvent mixture, e.g., ethanol/ethyl ether.
The pharmacology of acetaminophen is reviewed by B. Ameer et al., Ann. Int. Med., 87, 202 (1977), and the preparation of acetaminophen is disclosed in U.S. Pat. No. 2,998,450, which is incorporated herein by reference.
The APAP and the tramadol material are generally present in a weight ratio of tramadol material to APAP from about 1:1 to 1:1600. Certain ratios result in a composition which exhibits synergistic analgesic effects. For example, in a composition comprising a tramadol material and APAP, the ratio of the tramadol material: APAP is preferably from about 1:5 to 1:1600; and, more preferably, from about 1:19 to 1:800.
The most preferred ratios are from about 1:19 to 1:50. Compositions of a tramadol material and APAP within these weight ratios have been shown to exhibit synergistic analgesic effects. In addition, the particular compositions wherein the ratio of the components are about 1:1 and about 1:5 are encompassed by the present invention.
The tramadol/APAP formulations according to the present invention may also contain therapeutically effective amounts of one or more other pharmaceutical actives including but not limited to decongestants or bronchodilators (such as pseudoephedrine, phenylpropanolamine, phenylephrine and pharmaceutically acceptable salts thereof), antitussives (such as caraminophen, dextromethorphan and pharmaceutically acceptable salts thereof) antihistamines (such as chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbromphreniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, hydroxyzine, pyrilamine, azatadine, promethazine and pharmaceutically acceptable salts thereof), non-sedating antihistamines (such as acrivastine, astemizole, cetirizine, ketotifen, loratidine, temelastine, terfenadine (including the metabolites disclosed in U.S. Pat. No. 4,254,129 and 4,284,957 hereby incorporated by reference) and pharmaceutically acceptable salts thereof), muscle relaxants (such as glycerylmonether SMRS, methocarbamol, mephenesin, mephenesin carbamate, mephenesin acid succinate, cyclobenzaprine, chlorphenesin carbamate, chlorzoxazone or pharmceutically acceptable salts thereof) and suspected adjuvants (such as diphenhyhdramine, caffeine, xanthine derivatives (including those disclosed in U.S. Pat. No. 4,558,051, hereby incorporated by reference) and pharmaceutically acceptable salts thereof) and combinations of any of the aforesaid pharmaceuticals. The aforesaid pharmaceuticals may be combined with a tramadol/acetaminophen formulation for the treatment of such ailments as allergies, sleep disorders, cough, colds, cold-like and/or flu symptoms in mammals including humans.
Pharmaceutical compositions comprising the tramadol material and acetaminophen and when desired other pharmaceutical actives in an intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. The composition may also be administered by means of an aerosol. In preparing the compositions in an oral dosage form, any of the usual pharmaceutical media may be employed. For example, in the case of oral liquid preparations (such as suspensions, elixirs and solution), water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used. In the case of oral solid preparations (such as, for example, powders, capsules an tablets), carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like, may be used. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions will generally be in the form of a dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, containing from 0.1 to about 800 mg/kg, and preferably from about 0.3 to 200 mg/kg of the active ingredients. The dosage unit is calculated based on the amount of active which may be given to a 70 kg human subject in a single dose. The pharmaceutical compositions may be given at a daily dosage of from about 10 to 6000 mg/kg/day. However, it will be appreciated that the precise dose of the active ingredients will vary depending upon the relative amounts of active components being used. In the case wherein one or more other pharmaceutical components are added to the tramadol/APAP composition those components may be added in amounts known in the art and may be given at dosages conventional for such components. For example, decongestants and bronchodilators may be given in a single dosage of from about 12.5 to 75 mg/kg and at a daily dosage of from about 60 to 150 mg/kg/day. Antitussives may be given in a single dosage of from about 2.5 to 30 mg/kg and at a daily dosage of from about 20 to 120 mg/kg/day. Antihistamines may be given in a single dosage of from about 1 to 50 mg/kg and at a daily dosage of from about 4 to 600 mg/kg/day. Non-sedating antihistamines may be given in a single 1 dosage of from about 8 to 30 mg/kg and at a daily dosage of from about 30 to 120 mg/kg/day. Muscle relaxants may be given at a single dosage of from about 10 to 1500 mg/kg and at a daily dosage of from about 60 to 8000 mg/kg/day. Adjuvants may be given in a single dosage of from about 1 to 25 mg/kg and at a daily dosage of from about 1 to 100 mg/kg/day.
The following experimental examples describe the invention in greater particularly and are intended to be a way of illustrating but not limiting the invention.
The preparation of different ratios of a tramadol/APAP combination is effected by first preparing a stock solution of tramadol having a concentration expressed in mgdrugs per 10 mL of distilled water. For example, 8 mg of tramadol as the free base is dissolved per 10 mL of water to yield the highest dose of tramadol stock solution. The stock solution of the tramadol is then diluted with a sufficient amount of distilled water to prepare the lower doses of the tramadol per 10 mL of distilled water. The combinations are then made by adding 10 mL of each dilution to the appropriate mg of APAP to achieve the desired ratio of tramadol to APAP. For the 1:50 example: 400 mg of APAP as the free base is suspended with 10 mL of the 8 mg tramadol solution and 2 drops of TWEEN 80, a pharmacological dispersant, manufactured by Fisher Scientific Company, to yield the 1:50 ratio, i.e. (8 mg:400 mg) combination per 10 mL of water. Each ratio was prepared separately in a similar manner and injected in a volume of 10 mL/kg per mouse.
First, tramadol N-oxide was prepared as set forth hereinafter. Tramadol hydrochloride (0.5 mol) was converted to its free base in basified water (pH>9) and then extracted with ether. The ether was evaporated to yield the crystalline hydrate of tramadol. The solid was then heated with steam under a high vacuum to remove as much water as possible to yield 131.5 g of material. The material was dissolved in methanol (500 mL) and 65 g of 30% H2O2 was added. The solution was stirred for 3 hours and then an additional 65 g of the 30% H2O2 was added. The reaction was stirred for 2.5 days at room temperature. Approximately 10 mg of PtO2 on carbon (use of Pt/C is suggested for its ease of removal) was added to the reaction mixture, and very gentle foaming took place. An additional 10 mg of PtO2 was added and the reaction mixture was stirred overnight and then filtered thru a filter aid. The filtrate was concentrated under vacuum while being heated to a temperature of <40° C. The residue was taken up in methylene chloride. Since the methylene chloride solution contained some colloidial platinum, the solution was diluted with ethyl acetate to 1 L and filtered through a nylon filter membrane (0.45μ pore size) to yield a clear colorless filtrate. The filtrate was concentrated to 600 mL, and then ethyl acetate was added continuously to maintain a volume of 800 mL while the solution was heated until a vapor temperature of 74° C. was reached. The solution was then cooled to room temperature. The solid was collected by filtration, washed with ethyl acetate and dried in vacuo to yield 126.6 g of the tramadol N-oxide (mp. 159.5°-160° C.).
C16H25NO3 Theor.: C, 68.78; H, 9.27; N, 5.01 Found: C, 68.65; H, 9.22; N, 4.99
The preparation of different ratios of a tramadol N-oxide/APAP combination is effected by first preparing a stock solution of tramadol-N-oxide having a concentration expressed in mgdrugs per 10 mL of distilled water. For example, 8 mg of tramadol N-oxide as the free base is dissolved per 10 mL of water to yield the highest dose of tramadol stock solution. The stock solution of the tramadol-N-oxide is then diluted with a sufficient amount of distilled water to prepare the lower doses of the tramadol N-oxide per 10 mL of distilled water. The combinations are then made by adding 10 mL of each dilution to the appropriate mg of APAP to achieve the desired ratio of tramadol N-oxide to APAP. For the 1:50 example: 400 mg of APAP as the free base is suspended with 10 mL of the 8 mg tramadol N-oxide solution and 2 drops of TWEEN 80, a pharmacological dispersant, manufactured by Fisher Scientific Company, to yield the 1:50 ratio, i.e., (8 mg:400 mg) combination per 10 mL of water. Each ratio was prepared separately in a similar manner and injected in a volume of 10 mL/kg per mouse.
First, O-desmethyl tramadol was prepared as set forth hereinafter. Diethylene glycol (125 mL) was added with cooling to potassium hydride (9.5 g) with the temperature being maintained at <50° C. To the solution was added thiophenol (10 mL) dissolved in diethylene glycol (25 mL), and then (−)-tramadol as the free base (9.3 g) in diethylene glycol (50 mL) was added. The final reaction mixture was heated slowly to reflux for 45 minutes. The mixture was cooled and then quenched into water. The pH was adjusted to about 3, and the mixture was extracted with ethyl ether. The pH was readjusted to about 8 and the resulting mixture was extracted 5 more times with methylene chloride. The extract was dried and the methylene chloride was evaporated to yield 4.6 g of the title compound as an oil. The oil was distilled (Kugelrohr), dissolved in tetrahydrofuran, treated with an ethanol/HCl solution to give 2.3 g of the salt. The salt was recrystallized from ethanol/ethyl ether and dried to yield 1.80 g of the salt of the (−) enantiomer of O-desmethyl tramadol (mp. 242°-3° C.), [α]D25=−32.9 (C=1, EtOH).
C15H23NO2.HCl Theor.: C, 63.04; H, 8.46; N, 4.90 Found: C, 63.00; H, 8.51; N, 4.94
To prepare the (+) enantiomer of the title compound, the reaction was run under the same conditions except that (+)-tramadol as the free base was used instead of the (−)-tramadol to yield 2.8 g of the (+) enantiomer of O-desmethyl tramadol (mp. 242°-3° C.) [α]D25=+32.2 (C=1, EtOH).
C15H23NO2.HCl Theor.: C, 63.04; H, 8.46; N, 4.90 Found: C, 63.14; H, 8.49; N, 4.86
The preparation of different ratios of a O-desmethyl/APAP combination is effected by first preparing a stock solution of O-desmethyl tramadol having a concentration expressed in mgdrugs per 10 mL of distilled water. For example, 8 mg of O-desmethyl tramadol as the free base is dissolved per 10 mL of water to yield the highest dose of O-desmethyl tramadol stock solution. The stock solution of the O-desmethyl tramadol is then diluted with a sufficient amount of distilled water to prepare the lower doses of the O-desmethyl tramadol per 10 mL of distilled water. The combinations are then made by adding 10 mL of each dilution to the appropriate mg of APAP to achieve the desired ratio of O-desmethyl tramadol to APAP. For the 1:50 example: 400 mg of APAP as the free base is suspended with 10 mL of the 8 mg O-desmethyl tramadol solution and 2 drops of TWEEN 80, a pharmacological dispersant, manufactured by Fisher Scientific Company, to yield the 1:50 ratio, i.e., (8 mg: 400 mg) combination per 10 mL of water. Each ratio was prepared separately in a similar manner and injected in a volume of 10 ml/kg per mouse.
Male CD1 mice (weighing from 18-24 g) were utilized in determining the analgesic effects associated with the compositions of the invention. The mice were all dosed orally with tramadol hydrochloride (calculated as the base), which was completely dissolved in distilled water, and acetaminophen (calculated as the base), which was completely dissolved in distilled water or in distilled water containing 2% by volume of Tween 80 containing 100% polysorbate 80. The dosing volume was 10 mL/kg.
The procedure used in detecting and comparing the analgesic activity of different classes of analgesia drugs for which there is a good correlation with human efficacy is the prevention of acetylcholine-induced abdominal constriction in mice (H. Collier et al., Br. J. Pharmacol., 32, 295 (1968)).
Mice, intubated with various doses of tramadol hydrochloride alone, acetaminophen alone, combined doses of tramadol hydrochloride and acetaminophen, or vehicle such as distilled water, or distilled water containing 2% by volume of Tween 80, were injected intraperitoneally with a challenge dose of acetylcholine bromide. The acetylcholine was completely dissolved in distilled water at a concentration of 5.5 mg/kg and injected at the rate of 0.20 mL/20 g. For scoring purposes an “abdominal constriction” was defined as a contraction of the abdominal musculature accompanied by arching of the back and extension of the limbs. The mice were observed 10 minutes for the presence or absence of the abdominal constriction response beginning immediately after receiving the acetylcholine dose, which was 30 minutes after receiving the oral administration of tramadol hydrochloride, acetaminophen, combined doses of tramadol hydrochloride and acetaminophen, or vehicle. Each mouse was used only once.
The analysis of possible superadditivity for the compositions at each fixed ratio was determined as disclosed by R. J. Tallarida et al., Life Sci., 45, 947 (1989). This procedure involved the determination of the total amount in the mixture that is required to produce a specified level of effect, such as 50% (ED50mix), and the corresponding total amount that would be expected under simple additivity (ED50add). Where it was established that ED50mix<ED50add for a specific fixed-ratio, then that composition ratio was superadditive. Both the quantities ED50mix and ED50add were random variables; ED50mix was estimated from the dose-response curve for a specific fixed-ratio; ED50add was obtained by combining the ED50 estimates for the two drugs under additivity. ED50mix was then compared to ED50add via a Student's t-test. The ED50 value for tramadol hydrochloride alone was 5.5(4.8-6.4) mg/kg. The ED50 value for acetaminophen alone was 164.3 (122.7-219.9) mg/kg.
The interaction between tramadol and acetaminophen was determined at precise dosage ratios of tramadol hydrochloride and acetaminophen. Multiple (typically 4-6) coded doses of each selected combination were studied for analgesic effectiveness after 30 minutes using an experimental design which permitted the complete randomization of the separate dosage forms tested.
The interaction of tramadol hydrochloride and acetaminophen on the acetylcholine-induced abdominal constriction in mice was demonstrated by the data in Table I and is shown in the Loewe isobologram, FIG. I, (see, S. Loewe, Pharm. Rev., 9; 237 (1957) regarding the preparation and basis of an isobologram). In
TABLE 1
DRUG COMBINATIONS
DOSE (mg/kg, p.o.)
ED50 30 min (95% CI's)
(Tramadol:APAP)
Tramadol
APAP
analgesia
Tramadol
APAP
tramadol only
2
0
3/15
3
0
4/15
4
0
14/45
6
0
20/45
5.5
8
0
40/60
(4.8-6.4)
10
0
15/15
16
0
14/15
1000:1
3.75
0.00375
1/13
7.5
0.0075
8/15
7.0
0.01
15
0.015
15/15
(5.7-8.4)
(0.1-0.1)
100:1
1.875
0.01875
0/15
3.75
0.0375
4/15
6.9
0.1
7.5
0.075
5/15
(5.2-9.0)
(0.1-0.1)
15
0/15
15/15
20:1
1.875
0.09375
0.15
3.75
0.1875
4/15
6.5
0.3
7.5
0.375
7/15
(5.1-8.3)
(0.3-0.4)
15
0.75
15/15
3:1
3.75
1.25
3/30
7.5
2.5
12/30
7.8
2.6
15
5
28/30
(6.6-9.1)
(2.2-3.0)
1:1
0.94
0.94
3/15
1.875
1.875
8/30
3.75
3.75
14/30
3.8
3.8
5
5
12/28
(3.0-4.8)
(3.0-4.8)
7.5
7.5
24/30
15
15
15/15
1:3
3.75
11.25
7/30
5
15
7/15
4.7
14.2
7.5
22.5
29/30
(4.3-5.2)
(12.8-15.7)
1:5
2.5
12.5
7/30
5
25
8/30
4.0
19.8
10
50
30/30
(3.3-4.7)
(16.7-23.4)
1:5.7
0.47
2.66
0/15
0.94
5.313
4/15
1.88
10.625
1/15
4.1
23.3
3.75
21.25
5/15
(3.0-5.7)
(16.8-32.3)
7.5
42.5
11/15
15
85
15/15
1:19
0.94
17.813
4/30
1.88
36.625
10/28
3.75
71.25
21/30
2.5
47.3
5
95
22/30
(2.0-3.0)
(38.9-57.5)
7.5
142.5
29/30
15
285
15/15
1:50
0.25
12.5
3/30
0.5
25
7/30
1
50
9/30
1.2
61.4
2
100
19/30
(1.0-1.5)
(49.0-77.1)
4
200
27/30
8
400
30/30
1:100
0.25
25
3/60
0.5
50
12/60
1
100
19/60
1.1
111.3
2
200
51/60
(1.0-1.3)
(96.4-128.6)
4
400
55/60
8
800
30/30
1:200
0.125
25
1/60
0.25
50
9/60
0.5
100
27/60
0.6
129.7
1
200
44/60
(0.6-0.8)
(110.4-152.4)
2
400
48/60
4
800
30/30
1:400
0.0625
25
2/15
0.125
50
4/30
0.25
100
18/30
0.2
95.1
0.5
200
12/15
(0.2-0.3)
(75.4-119.8)
1
400
28/30
2
800
15/15
1:800
0.03125
25
4/30
0.0625
50
9/30
0.125
100
15/30
0.1
77.4
0.25
200
27/30
(0.1-0.1)
(62.9-95.2)
0.5
400
30/30
1:1600
0.03125
50
2/30
0.0625
100
14/30
0.125
200
22/30
0.1
125.7
0.25
400
27/30
(0.1-0.1)
(102.7-153.8)
0.5
800
30/30
APAP only
0
30
2/15
0
40
12/43
0
50
1/15
0
60
8/30
0
80
23/60
0
100
13/30
—
164.3
0
120
13/30
(122.7-219.9)
0
160
10/30
0
200
13/25
0
240
14/25
0
400
12/15
0
800
13/15
Raffa, Robert B., Vaught, Jeffrey L.
| Patent | Priority | Assignee | Title |
| 10016368, | Jul 08 2009 | LOCL PHARMA, INC. | Pharmaceutical compositions for treating or preventing pain |
| 10064856, | Jan 09 2008 | LOCAL PHARMA, INC. | Pharmaceutical compositions |
| 10179109, | Mar 04 2016 | CHARLESTON LABORATORIES, INC | Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates |
| 10532030, | Jul 08 2009 | LOCL PHARMA, INC. | Pharmaceutical compositions for treating or preventing pain |
| 10772840, | Mar 04 2016 | CHARLESTON LABORATORIES, INC. | Sumatriptan promethazine pharmaceutical compositions |
| 7829120, | Sep 09 2005 | ANGELINI PHARMA INC | Trazodone composition for once a day administration |
| 7988998, | Oct 25 2002 | Paladin Labs Europe Limited | Sustained-release tramadol formulations with 24-hour efficacy |
| 8124126, | Jan 09 2008 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 8414919, | Sep 09 2005 | ANGELINI PHARMA INC | Sustained drug release composition |
| 8486448, | Dec 17 2007 | Paladin Labs Europe Limited | Misuse preventative, controlled release formulation |
| 8486449, | Dec 16 2008 | 9254-0145 QUEBEC INC FORMERLY KNOWN AS LABOPHARM INC - PARTIAL INTEREST ENTIRE INTEREST OWNED BY 9254-0145 QUEBEC INC , PALADIN LABS EUROPE LIMITED, AND LABOPHARM BARBADOS LIMITED ; PALADIN LABS EUROPE LIMITED FORMERLY KNOWN AS LABOPHARM EUROPE LIMITED - PARTIAL INTEREST ENTIRE INTEREST OWNED BY 9254-0145 QUEBEC INC , PALADIN LABS EUROPE LIMITED, AND LABOPHARM BARBADOS LIMITED ; LABOPHARM BARBADOS LIMITED - PARTIAL INTEREST ENTIRE INTEREST OWNED BY 9254-0145 QUEBEC INC , PALADIN LABS EUROPE LIMITED, AND LABOPHARM BARBADOS LIMITED | Misuse preventative, controlled release formulation |
| 8487002, | Oct 25 2002 | Paladin Labs Europe Limited | Controlled-release compositions |
| 8653066, | Oct 09 2006 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 8685447, | Dec 16 2008 | Paladin Labs Inc.; Paladin Labs (Barbados) Inc.; Paladin Labs Europe Limited | Misuse preventative, controlled release formulation |
| 8691270, | Dec 17 2007 | Paladin Labs Inc.; Paladin Labs (Barbados) Inc.; Paladin Labs Europe Limited | Misuse preventative, controlled release formulation |
| 8728522, | Jul 08 2009 | LOCL PHARMA, INC | Pharmaceutical compositions for treating or preventing pain |
| 8795723, | Sep 09 2005 | ANGELINI PHARMA INC | Sustained drug release compositions |
| 8895066, | Oct 16 2007 | Paladin Labs Europe Limited | Bilayer composition for the sustained release of acetaminophen and tramadol |
| 8920833, | Dec 17 2007 | Paladin Labs Inc.; Paladin Labs (Barbados) Inc.; Paladin Labs Europe Limited | Misuse preventative, controlled release formulation |
| 8920834, | Dec 17 2007 | Paladin Labs Inc.; Paladin Labs (Barbados) Inc.; Paladin Labs Europe Limited | Misuse preventative, controlled release formulation |
| 8927013, | Dec 16 2008 | Paladin Labs Inc.; Paladin Labs (Barbados) Inc.; Paladin Labs Europe Limited | Misuse preventative, controlled release formulation |
| 8927014, | Dec 16 2008 | Paladin Labs Inc.; Paladin Labs (Barbados) Inc.; Paladin Labs Europe Limited | Misuse preventative, controlled release formulation |
| 8962019, | Sep 09 2005 | ANGELINI PHARMA INC | Sustained drug release composition |
| 9198867, | Jan 09 2008 | CHARLESTON LABORATORIES, INC | Pharmaceutical compositions |
| 9226901, | Jan 09 2008 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9387177, | Jan 09 2008 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9393207, | Oct 09 2006 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9399022, | Oct 09 2006 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9402813, | Oct 09 2006 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9427407, | Oct 09 2006 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9433625, | Jul 08 2009 | LOCL PHARMA, INC | Pharmaceutical compositions for treating or preventing pain |
| 9439866, | Sep 09 2005 | ANGELINI PHARMA INC | Trazodone composition for once a day administration |
| 9498444, | Jan 09 2008 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9526704, | Jul 08 2009 | LOCL PHARMA, INC. | Pharmaceutical compositions for treating or preventing pain |
| 9775837, | Jan 09 2008 | CHARLESTON LABORATORIES, INC. | Pharmaceutical compositions |
| 9789104, | Jan 09 2008 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9789105, | Jan 09 2008 | LOCL PHARMA, INC | Pharmaceutical compositions |
| 9855264, | Jan 09 2008 | LOCL PHARMA, INC. | Pharmaceutical compositions |
| RE40602, | Dec 24 1997 | Panasonic Corporation | Semiconductor device having a ferroelectric TFT and a dummy element |
| Patent | Priority | Assignee | Title |
| 2770569, | |||
| 3652589, | |||
| 3773955, | |||
| 3830934, | |||
| 4132788, | May 04 1976 | McNeil Laboratories, Inc. | Antiarthritic potentiation |
| 4237140, | May 18 1979 | Dupont Pharmaceuticals Company | Analgesic mixture of nalbuphine and acetaminophen |
| 4260629, | Oct 25 1979 | Dupont Pharmaceuticals Company | Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid |
| 4322427, | Apr 16 1981 | Bristol-Myers Company | Analgetic compositions and methods of use |
| 4571400, | Dec 18 1984 | JOHN AND LOIS ARNOLD FAMILY LIMITED LIABILITY PARTNERSHIP | Dihydrocodeine/ibuprofen pharmaceutical compositions and method |
| 4601894, | Mar 29 1985 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
| 4631284, | Nov 19 1984 | MALLINCKRODT SPECIALTY CHEMICALS COMPANY, A DE CORP | Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom |
| 4730007, | Sep 04 1985 | ENDORFIN, INC | Novel analgesic compositions |
| 4769372, | Jun 18 1986 | Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| 4806543, | Nov 25 1986 | Board of Trustees of the Leland Stanford Junior University; BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE, STANFORD UNIVERSITY, A CA CORP | Method and compositions for reducing neurotoxic injury |
| 4829064, | Jun 08 1987 | ANALGESIC ASSOCIATES, 34 DANTE STREET, LARCHMONT, NEW YORK 10538 A CORP OF NEW YORK | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| 4943565, | Sep 15 1986 | Novartis AG | Analgesic tablet of aspirin and caffeine containing low-substituted hydroxypropyl cellulose |
| 5223541, | Sep 13 1991 | McNeilab, Inc. | Tramadol N-oxide material, enantiomers and compositions thereof, and their use |
| 5317022, | Feb 04 1991 | ICN HUNGARY RT | Pharmaceutical composition and use |
| 5352680, | Jul 15 1992 | Regents of the University of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
| 5468744, | Sep 06 1991 | McNeil Lab, Inc. | Composition comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use |
| 5516803, | Oct 30 1991 | McNeilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| 6562865, | Aug 20 1999 | Ortho-McNeil Pharmaceutical, Inc | Composition comprising a tramadol material and an anticonvulsant drug |
| EP17102, | |||
| EP227836, | |||
| EP240904, | |||
| EP358105, | |||
| EP358107, | |||
| JP5492631, | |||
| JP55129225, | |||
| JP55154917, | |||
| JP57128626, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Dec 18 1997 | ORTHO PHARMACUETICAL CORPORATION | ORTHO-MCNEIL PHARAMACEUTICAL, INC | MERGER SEE DOCUMENT FOR DETAILS | 017507 | /0355 | |
| Dec 18 1997 | MCNEILAB, INC | ORTHO-MCNEIL PHARAMACEUTICAL, INC | MERGER SEE DOCUMENT FOR DETAILS | 017507 | /0355 | |
| Dec 18 1997 | Ortho Pharmaceutical Corporation | Ortho-McNeil Pharmaceutical, Inc | CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST ASSIGNOR: PHARMACUETICAL SHOULD READ PHARMACEUTICAL AND ASSIGNEE: PHARAMEUTICAL SHOULD READ PHARMACEUTICAL PREVIOUSLY RECORDED ON REEL 017507 FRAME 0355 ASSIGNOR S HEREBY CONFIRMS THE CONVEYING AND RECEIVING PARTY DATA CONTAIN A TYPOGRAPHICAL ERROR | 017507 | /0655 | |
| Dec 18 1997 | MCNEILAB, INC | Ortho-McNeil Pharmaceutical, Inc | CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST ASSIGNOR: PHARMACUETICAL SHOULD READ PHARMACEUTICAL AND ASSIGNEE: PHARAMEUTICAL SHOULD READ PHARMACEUTICAL PREVIOUSLY RECORDED ON REEL 017507 FRAME 0355 ASSIGNOR S HEREBY CONFIRMS THE CONVEYING AND RECEIVING PARTY DATA CONTAIN A TYPOGRAPHICAL ERROR | 017507 | /0655 | |
| Jan 20 2004 | Ortho-McNeil Pharmaceutical, Inc. | (assignment on the face of the patent) | / | |||
| Jan 19 2008 | Ortho-McNeil Pharmaceutical, Inc | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC | AGREEMENT FOR TRANSFER OF ASSETS AND BILL OF SALE | 021478 | /0158 |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Aug 01 2009 | 4 years fee payment window open |
| Feb 01 2010 | 6 months grace period start (w surcharge) |
| Aug 01 2010 | patent expiry (for year 4) |
| Aug 01 2012 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Aug 01 2013 | 8 years fee payment window open |
| Feb 01 2014 | 6 months grace period start (w surcharge) |
| Aug 01 2014 | patent expiry (for year 8) |
| Aug 01 2016 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Aug 01 2017 | 12 years fee payment window open |
| Feb 01 2018 | 6 months grace period start (w surcharge) |
| Aug 01 2018 | patent expiry (for year 12) |
| Aug 01 2020 | 2 years to revive unintentionally abandoned end. (for year 12) |